ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0159

Patient-Reported Data Show the Impact of Time to Diagnosis in RA

Kelly O'Neill1, Kathryne Marks2, John Davis3 and Cynthia Crowson4, 1Rheumatoid Patient Foundation, Orlando, FL, 2Rosalind Franklin University of Medicine and Science, North Chicago, IL, 3Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

Meeting: ACR Convergence 2020

Keywords: Diagnostic criteria, Disease Activity, Patient reported outcomes, rheumatoid arthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Time from diagnosis to treatment has been well established to correlate with better outcomes in rheumatoid arthritis (RA). Treatment delays are often associated with worse outcomes and more difficult to treat disease, while early and aggressive treatment leads to better outcomes and increased levels of rheumatoid disease activity (DA) improvement. However time from symptom onset to diagnosis has been less discussed. Building on a collaboration between a non-profit organization and an academic rheumatology center, we aimed to gain greater understanding of the impact of time from symptom onset to diagnosis of RA.

Methods: An anonymous 28-item questionnaire was developed and pilot-tested by the study team and presented in 2019 on a secure online survey system. Eligible participants were U.S. residents age ≥18 years with a self-reported diagnosis of RA by a medical professional. They were asked questions about socio-demographics, RA disease activity, diagnosis and DMARD history, improvement from RA treatment, and RA treatment goals created with their provider. Analyses included descriptive statistics with chi-square and rank sum tests for comparisons.

Results: The questionnaire was completed by 907 self-reported RA patients (90% women, 10% men), with a mean (SD) age of 58 years and a mean of 11.1 (10.1) years since diagnosis. According to patient self-reports, 5% were in remission, 22% reported mild DA, 54% moderate DA, and 19% severe DA.

The longer the time to diagnosis, the more likely people were to report moderate to severe DA levels (< 6mo 65%; >6mo-5yr 75%; >5yr 80%). Similarly, people with a shorter time to diagnosis were twice as likely to reach DA improvement levels ≥70% as those with long times to diagnosis (< 6mo 48%; >6mo-5yr 38%; >5yr 24%).

Longer times from symptom onset to diagnosis also associated with longer times between RA diagnosis and eventual treatment. When the time from symptom onset to diagnosis was < 6 months, time from RA diagnosis to treatment was only an additional 0.8 years. However for those whose diagnosis took >5 years, time from RA diagnosis to treatment initiation was an average of an additional 1.5 years.

The longer the time to diagnosis, the less satisfaction and greater dissatisfaction people with RA had with their rheumatology care (satisfied/very satisfied was reported in: < 6mo 76%; >6mo-5yr 71%; >5yr 65%). Additionally, those describing their health as poor/very poor tended to have longer times to diagnosis (< 6mo 18%; >6mo-5yr 21%; >5yr 27%).

Conclusion: This web-based survey found previously unreported associations between time from symptom onset to RA diagnosis and more severe disease activity and lower responses to treatment, independent of time to between RA diagnosis and treatment initiation. Our study is unique in that time to diagnosis and / or to treatment are reported by patients with RA. Further research should seek greater understanding of the significance of early RA diagnosis and investigate ways to decrease times from symptom onset to RA diagnosis.

Fig.1 Current RA Disease Activity Level Versus Time to Diagnosis

Fig.2 Disease Activity Improvement Level by Time to Diagnosis

Table1 Responses by Time from Symptom Onset to RA Diagnosis


Disclosure: K. O'Neill, None; K. Marks, None; J. Davis, Pfizer, 2, AbbVie, 5, 8, Sanofi-Genzyme, 5, 8; C. Crowson, Myriad Genetics, 1, Pfizer, 1.

To cite this abstract in AMA style:

O'Neill K, Marks K, Davis J, Crowson C. Patient-Reported Data Show the Impact of Time to Diagnosis in RA [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patient-reported-data-show-the-impact-of-time-to-diagnosis-in-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-data-show-the-impact-of-time-to-diagnosis-in-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology